Unicycive Therapeutics Valuation
| UNCY Stock | USD 0.68 0.03 4.62% |
Unicycive Therapeutics is overvalued. Unicycive Therapeutics has a current Real Value of $0.56 per share. The regular price of the company is $0.68. Our model measures the value of Unicycive Therapeutics from inspecting the company fundamentals such as Shares Owned By Institutions of 60.39 %, shares outstanding of 103.8 M, and Return On Equity of -1.47 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Unicycive Therapeutics' valuation include:
Price Book 2.5343 | Enterprise Value | Enterprise Value Ebitda (1.03) | Price Sales 62.819 | Enterprise Value Revenue 16.632 |
Overvalued
Today
Please note that Unicycive Therapeutics' price fluctuation is abnormally volatile at this time. Calculation of the real value of Unicycive Therapeutics is based on 3 months time horizon. Increasing Unicycive Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Unicycive Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Unicycive Stock. However, Unicycive Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.68 | Real 0.56 | Target 5.5 | Hype 0.68 | Naive 0.78 |
The intrinsic value of Unicycive Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Unicycive Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Unicycive Therapeutics helps investors to forecast how Unicycive stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Unicycive Therapeutics more accurately as focusing exclusively on Unicycive Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Unicycive Therapeutics' intrinsic value based on its ongoing forecasts of Unicycive Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Unicycive Therapeutics' closest peers.
Unicycive Therapeutics Cash |
|
Unicycive Valuation Trend
Analysing the historical paterns of Unicycive Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Unicycive Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Unicycive Therapeutics Total Value Analysis
Unicycive Therapeutics is at this time forecasted to have valuation of 39.04 M with market capitalization of 70.58 M, debt of 811 K, and cash on hands of 10.57 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Unicycive Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
39.04 M | 70.58 M | 811 K | 10.57 M |
Unicycive Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Unicycive Therapeutics has an asset utilization ratio of 4.76 percent. This suggests that the Company is making $0.0476 for each dollar of assets. An increasing asset utilization means that Unicycive Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Unicycive Therapeutics Ownership Allocation
Unicycive Therapeutics shows a total of 103.8 Million outstanding shares. Over half of Unicycive Therapeutics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Unicycive Therapeutics Profitability Analysis
The company reported the previous year's revenue of 675 K. Net Loss for the year was (30.54 M) with profit before overhead, payroll, taxes, and interest of 0.About Unicycive Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Unicycive Therapeutics. We calculate exposure to Unicycive Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Unicycive Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 776.2 K | 595.8 K | |
| Pretax Profit Margin | (52.04) | (54.64) | |
| Operating Profit Margin | (35.39) | (37.16) | |
| Net Loss | (52.04) | (54.64) | |
| Gross Profit Margin | 0.89 | 0.79 |
Unicycive Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 24.5 M |
Unicycive Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Unicycive Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Unicycive we look at many different elements of the entity such as Unicycive's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Unicycive Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Unicycive Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Unicycive Therapeutics' worth.Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.